Dasatinib is a tyrosine kinase inhibitor originally developed to treat certain types of cancer in humans, particularly chronic myeloid leukemia. In the context of canine longevity, it has garnered attention for its ability to target and eliminate senescent cells—cells that have stopped dividing and can contribute to age-related decline. Research has explored its potential in improving health spans and possibly extending longevity by addressing underlying cellular aging processes in dogs.
Why it matters
Understanding Dasatinib and its role in canine longevity can help dog owners stay informed about emerging treatments that may enhance their pets' quality of life as they age.